{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:14:35Z","timestamp":1742876075444,"version":"3.40.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91540-9","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:46:17Z","timestamp":1742859977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Chunyan","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruigang","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"91540_CR1","doi-asserted-by":"publisher","first-page":"1223020","DOI":"10.3389\/fimmu.2023.1223020","volume":"14","author":"G Xiang","year":"2023","unstructured":"Xiang, G. et al. Cost-effectiveness of Serplulimab as first-line therapy for extensive-stage small cell lung cancer in China. Front. Immunol. 14, 1223020. https:\/\/doi.org\/10.3389\/fimmu.2023.1223020 (2023).","journal-title":"Front. Immunol."},{"key":"91540_CR2","doi-asserted-by":"publisher","first-page":"1142081","DOI":"10.3389\/fonc.2023.1142081","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang, S. & Cheng, Y. Immunotherapy for extensive-stage small-cell lung cancer: Current landscape and future perspectives. Front. Oncol. 13, 1142081. https:\/\/doi.org\/10.3389\/fonc.2023.1142081 (2023).","journal-title":"Front. Oncol."},{"key":"91540_CR3","doi-asserted-by":"publisher","first-page":"1156427","DOI":"10.3389\/fpubh.2023.1156427","volume":"11","author":"X Liang","year":"2023","unstructured":"Liang, X., Chen, X., Li, H. & Li, Y. Cost-effectiveness analysis of first-line Serplulimab combined with chemotherapy for extensive-stage small cell lung cancer. Front. Public. Health. 11, 1156427. https:\/\/doi.org\/10.3389\/fpubh.2023.1156427 (2023).","journal-title":"Front. Public. Health"},{"key":"91540_CR4","doi-asserted-by":"publisher","first-page":"1019826","DOI":"10.3389\/fphar.2022.1019826","volume":"13","author":"M You","year":"2022","unstructured":"You, M. et al. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer. Front. Pharmacol. 13, 1019826. https:\/\/doi.org\/10.3389\/fphar.2022.1019826 (2022).","journal-title":"Front. Pharmacol."},{"key":"91540_CR5","doi-asserted-by":"publisher","first-page":"1259574","DOI":"10.3389\/fonc.2023.1259574","volume":"13","author":"Z Zheng","year":"2023","unstructured":"Zheng, Z., Chen, H. & Cai, H. Cost-effectiveness analysis of Serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer. Front. Oncol. 13, 1259574. https:\/\/doi.org\/10.3389\/fonc.2023.1259574 (2023).","journal-title":"Front. Oncol."},{"key":"91540_CR6","doi-asserted-by":"publisher","first-page":"1028202","DOI":"10.3389\/fpubh.2023.1028202","volume":"11","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Liu, K., Yang, Q., Zeng, M. & Peng, L. First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis. Front. Public. Health. 11, 1028202. https:\/\/doi.org\/10.3389\/fpubh.2023.1028202 (2023).","journal-title":"Front. Public. Health"},{"issue":"10","key":"91540_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","volume":"19","author":"D Ding","year":"2021","unstructured":"Ding, D. et al. Cost-Effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J. Natl. Compr. Canc Netw. 19 (10), 1141\u20131147. https:\/\/doi.org\/10.6004\/jnccn.2020.7796 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"91540_CR8","doi-asserted-by":"publisher","unstructured":"Kang, S. & Liu, H. Cost-effectiveness of adding Serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev. Pharmacoecon Outcomes Res. 1\u20138. https:\/\/doi.org\/10.1080\/14737167.2023.2281606 (2023).","DOI":"10.1080\/14737167.2023.2281606"},{"issue":"11","key":"91540_CR9","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/ijc.34346","volume":"152","author":"Y Yu","year":"2023","unstructured":"Yu, Y., Chen, K. & Fan, Y. Extensive-stage small-cell lung cancer: current management and future directions. Int. J. Cancer. 152 (11), 2243\u20132256. https:\/\/doi.org\/10.1002\/ijc.34346 (2023).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"91540_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty, W. J. & Paz-Ares, L. Emerging strategies for the treatment of small cell lung cancer: A review. JAMA Oncol. 9 (3), 419\u2013429. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631 (2023).","journal-title":"JAMA Oncol."},{"issue":"12","key":"91540_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y. et al. Effect of First-Line Serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial. Jama 328 (12), 1223\u20131232. https:\/\/doi.org\/10.1001\/jama.2022.16464 (2022).","journal-title":"Jama"},{"issue":"23","key":"91540_CR12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-Line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl. J. Med. 379 (23), 2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064 (2018).","journal-title":"N Engl. J. Med."},{"issue":"10212","key":"91540_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 394 (10212), 1929\u20131939. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6 (2019).","journal-title":"Lancet"},{"issue":"6","key":"91540_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Adebrelimab or placebo plus carboplatin and Etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23 (6), 739\u2013747. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8 (2022).","journal-title":"Lancet Oncol."},{"key":"91540_CR15","doi-asserted-by":"publisher","first-page":"1044678","DOI":"10.3389\/fimmu.2022.1044678","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Liu, K., Qin, Q. & Zhu, H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front. Immunol. 13, 1044678. https:\/\/doi.org\/10.3389\/fimmu.2022.1044678 (2022).","journal-title":"Front. Immunol."},{"key":"91540_CR16","doi-asserted-by":"publisher","unstructured":"Benmelstobart Ups ES-SCLC Survival. Cancer Discov 13(11), 2296\u20132297. https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2023-0069 (2023).","DOI":"10.1158\/2159-8290.Cd-nb2023-0069"},{"key":"91540_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03132-1","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial. Nat. Med. Https\/\/. https:\/\/doi.org\/10.1038\/s41591-024-03132-1 (2024).","journal-title":"Nat. Med. Https\/\/"},{"key":"91540_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.019","volume":"130","author":"K Zhou","year":"2019","unstructured":"Zhou, K. et al. Cost-effectiveness analysis of Atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 130, 1\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.019 (2019).","journal-title":"Lung Cancer"},{"issue":"10","key":"91540_CR19","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1007\/s12325-021-01889-2","volume":"38","author":"J Gong","year":"2021","unstructured":"Gong, J. et al. Cost-effectiveness analysis of anlotinib as third- or further-line treatment for relapsed small cell lung cancer (SCLC) in China. Adv. Ther. 38 (10), 5116\u20135126. https:\/\/doi.org\/10.1007\/s12325-021-01889-2 (2021).","journal-title":"Adv. Ther."},{"issue":"8","key":"91540_CR20","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.21037\/tlcr-23-456","volume":"12","author":"Q Zhu","year":"2023","unstructured":"Zhu, Q., Ni, R. & Guan, X. Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China. Transl Lung Cancer Res. 12 (8), 1782\u20131789. https:\/\/doi.org\/10.21037\/tlcr-23-456 (2023).","journal-title":"Transl Lung Cancer Res."},{"issue":"11","key":"91540_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han, B. et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced Non-Small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4 (11), 1569\u20131575. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039 (2018).","journal-title":"JAMA Oncol."},{"issue":"3","key":"91540_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","volume":"125","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study. Br. J. Cancer. 125 (3), 366\u2013371. https:\/\/doi.org\/10.1038\/s41416-021-01356-3 (2021).","journal-title":"Br. J. Cancer"},{"issue":"8","key":"91540_CR23","doi-asserted-by":"publisher","first-page":"e072106","DOI":"10.1136\/bmjopen-2023-072106","volume":"13","author":"Y Long","year":"2023","unstructured":"Long, Y., Xu, Y., Liao, L., Zhou, Y. & Wang, H. Cost-effectiveness analysis of Serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China. BMJ Open. 13 (8), e072106. https:\/\/doi.org\/10.1136\/bmjopen-2023-072106 (2023).","journal-title":"BMJ Open."},{"issue":"1","key":"91540_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Value Health 25 (1), 3\u20139. (2022). https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351 (2022).","journal-title":"Value Health"},{"issue":"4","key":"91540_CR25","doi-asserted-by":"publisher","first-page":"e077090","DOI":"10.1136\/bmjopen-2023-077090","volume":"14","author":"Y Long","year":"2024","unstructured":"Long, Y. et al. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China. BMJ Open. 14 (4), e077090. https:\/\/doi.org\/10.1136\/bmjopen-2023-077090 (2024).","journal-title":"BMJ Open."},{"issue":"4","key":"91540_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989x16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams, C., Lewsey, J. D., Mackay, D. F. & Briggs, A. H. Estimation of survival probabilities for use in cost-effectiveness analyses: A comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med. Decis. Mak. 37 (4), 427\u2013439. https:\/\/doi.org\/10.1177\/0272989x16670617 (2017).","journal-title":"Med. Decis. Mak."},{"key":"91540_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue, X., Li, Y., Wu, J. & Guo, J. J. Current development and practice of Pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg. Issues. 24, 1\u20135. https:\/\/doi.org\/10.1016\/j.vhri.2020.07.580 (2021).","journal-title":"Value Health Reg. Issues"},{"key":"91540_CR28","unstructured":"Liu, G. et al. China Guidelines for Pharmacoeconomic Evaluations. 6\u20139\u2009+\u200911\u201348 (China Market Publishing House, 2011)."},{"key":"91540_CR29","unstructured":"NBS. Statistical Communique of the People\u2019s Republic of Chinaon the 2023 National Economic and Social Development. Available online at: (2024). https:\/\/www.stats.gov.cn\/sj\/zxfb\/202402\/t20240228_1947915.html. Accessed May 15, 2024."},{"key":"91540_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot, P., Ades, A. E., Ouwens, M. J. & Welton, N. J. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9. https:\/\/doi.org\/10.1186\/1471-2288-12-9 (2012).","journal-title":"BMC Med. Res. Methodol."},{"issue":"6","key":"91540_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989x12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer, N. R. Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: Inconsistencies, limitations, and a practical guide. Med. Decis. Mak. 33 (6), 743\u2013754. https:\/\/doi.org\/10.1177\/0272989x12472398 (2013).","journal-title":"Med. Decis. Mak."},{"key":"91540_CR32","unstructured":"Yao, Z. H. The big data service platform for china\u2019s health industry: information query of drug bid winning Available online at: Preprint at: (2023). https:\/\/data.yaozh.com\/. Accessed 06 April 2024."},{"key":"91540_CR33","doi-asserted-by":"publisher","first-page":"935581","DOI":"10.3389\/fphar.2022.935581","volume":"13","author":"X Luo","year":"2022","unstructured":"Luo, X., Zhou, Z., Zeng, X. & Liu, Q. The cost-effectiveness of Tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung Cancer. Front. Pharmacol. 13, 935581. https:\/\/doi.org\/10.3389\/fphar.2022.935581 (2022).","journal-title":"Front. Pharmacol."},{"key":"91540_CR34","doi-asserted-by":"publisher","first-page":"728440","DOI":"10.3389\/fphar.2021.728440","volume":"12","author":"L Qiao","year":"2021","unstructured":"Qiao, L., Zhou, Z., Zeng, X. & Tan, C. Cost-Effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non-small-cell lung cancer in China. Front. Pharmacol. 12, 728440. https:\/\/doi.org\/10.3389\/fphar.2021.728440 (2021).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"91540_CR35","doi-asserted-by":"publisher","first-page":"e0232240","DOI":"10.1371\/journal.pone.0232240","volume":"15","author":"S Li","year":"2020","unstructured":"Li, S. et al. Cost-Effectiveness of ramucirumab plus Paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS One. 15 (5), e0232240. https:\/\/doi.org\/10.1371\/journal.pone.0232240 (2020).","journal-title":"PLoS One"},{"issue":"6","key":"91540_CR36","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s11096-024-01802-1","volume":"46","author":"W Lang","year":"2024","unstructured":"Lang, W. et al. Cost-effectiveness analysis of Tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the united States and China. Int. J. Clin. Pharm. 46 (6), 1536\u20131545. https:\/\/doi.org\/10.1007\/s11096-024-01802-1 (2024).","journal-title":"Int. J. Clin. Pharm."},{"issue":"5","key":"91540_CR37","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees, B., Lloyd, A. J., Dewilde, S., Rajan, N. & Lorenzo, M. Health state utilities in non-small cell lung cancer: An international study. Asia Pac. J. Clin. Oncol. 13 (5), e195\u2013e203. https:\/\/doi.org\/10.1111\/ajco.12477 (2017).","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"10","key":"91540_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2014.58.4904","volume":"33","author":"DA Goldstein","year":"2015","unstructured":"Goldstein, D. A. et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J. Clin. Oncol. 33 (10), 1112\u20131118. https:\/\/doi.org\/10.1200\/jco.2014.58.4904 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"91540_CR39","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMsa1203980","volume":"367","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y., Baik, S. H., Fendrick, A. M. & Baicker, K. Comparing local and regional variation in health care spending. N Engl. J. Med. 367 (18), 1724\u20131731. https:\/\/doi.org\/10.1056\/NEJMsa1203980 (2012).","journal-title":"N Engl. J. Med."},{"key":"91540_CR40","unstructured":"China, C. P. s. G. o. t. P. s. R. o. Catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance (2020), Available online at: (2020). http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-12\/28\/content_5574062.htm. Accessed 15 May  2024."},{"issue":"10","key":"91540_CR41","doi-asserted-by":"publisher","first-page":"e48323","DOI":"10.1371\/journal.pone.0048323","volume":"7","author":"X Zeng","year":"2012","unstructured":"Zeng, X. et al. The cost of treating advanced non-small cell lung cancer: Estimates from the Chinese experience. PLoS One. 7 (10), e48323. https:\/\/doi.org\/10.1371\/journal.pone.0048323 (2012).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91540-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:46:33Z","timestamp":1742859993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91540"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91540-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10147"}}